Exosens stock among the steepest declines on the SBF 120 despite +10% over three months

A decline that contrasts with the solid performance over three months

Exosens falls 2.33% to €60.80 mid-morning, posting the second-worst performance on the SBF 120 while the Paris index gains 0.43%. This decline is part of a turbulent sequence since the spectacular rebound in mid-September: following the upward revision of annual targets on September 17, the stock had surged approximately 10% during the session, then continued its advance the next day with a 3.5% gain before consolidating. Over three months, the performance remains solid at +10.24%, and over one year, gains exceed 39%.

Today's decline thus dampens an overall favorable sequence without erasing its trend. Bernstein furthermore raised its target on September 23 to €74, versus €71.50 previously, while maintaining its outperform rating, which represents an upside potential of approximately 22% compared to the current price.

A technical setup that remains favorable despite today's pressure

Despite the decline, the stock remains anchored above its three moving averages: the 20-day MA at €57.95, the 50-day MA at €59.89 and the 200-day MA at €59.31, with respective gaps of +4.92%, +1.52% and +2.51%. It is precisely this positioning that distinguishes the current situation from that of early September, when the stock was trading below all of these benchmarks. The RSI at 60 remains in neutral-bullish territory, with no overbought signal, which leaves technical room before reaching the resistance at €66.80.

Support, meanwhile, stands at €54.15, approximately 11% below the current price. The next nine-month results, expected on October 27, 2026, will constitute the next fundamental benchmark for assessing the group's trajectory.